Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

PURPOSE: To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in EGFR. PATIENTS AND METHODS: Patients with resectable stage I and II non-small cell lung cancer (NSCLC) enriched for the likelihood of EGFR mutation (≤ 15 pack year ci...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rizvi, Naiyer A., Pao, William, Chaft, Jamie E., Ladanyi, Marc, Miller, Vincent A., Krug, Lee M., Azzoli, Christopher G., Bains, Manjit, Downey, Robert, Flores, Raja, Park, Bernard, Rusch, Valerie, Zakowski, Maureen, Heelan, Robert T., Shen, Ronglai, Kris, Mark G.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3261615/
https://ncbi.nlm.nih.gov/pubmed/21558399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2102
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires